[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysphagia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysphagia":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,45,69,94,124,154,178,210,235,262,284,307,329,369,397,430,453,476,503,530,558,590,611,633,655],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100595082","the-esophageal-string-test-as-a-diagnostic-screening-tool-for-eosinophilic-esophagitis-among-africans-with-dysphagia-in-mali-and-the-united-states-100595082",false,"NCT07027826","The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States","Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Able to provide informed consent.\n2. Aged 18 to 65 years.\n3. Born in the African continent or their parents were born in Africa,\n4. Exhibiting symptoms of dysphagia and\u002For prior history of food impaction.\n5. Undergoing clinically indicated endoscopy at the NIH Clinical Center (U.S.), Centre Hospitalier Universitaire Gabriel Tour(SqrRoot)(Copyright) (Mali), or other local clinics (Mali) and willing to provide research samples and data.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Recent steroid use (systemic or swallowed\u002Ftopical corticosteroid) within 4 weeks prior to endoscopy.\n2. Recent use of dupilumab (Dupixent) within the last 6 months.\n3. Recent use of other biologic medications (within either 6 months or 5 half-lives, whichever is longer). Examples of biologic medications include:\n\n3a. mepolizumab (Nucala)\n\n3b. reslizumab (Cinqair, Cinqaero)\n\n3c. benralizumab (Fasenra)\n\n3d. cendakimab\n\n3e. tezepelumab (Tezspire)\n\n3f. barzolvolimab\n\n4\\. Individuals suffering from a bleeding diathesis (e.g., hemophilia, severe thrombocytopenia).\n\n5\\. Current use of anticoagulant medications.\n\n6\\. Pregnancy.\n\n7\\. Treatment with another investigational drug or other investigational intervention within 6 months or 5 half-lives whichever is longer.\n\n8\\. Individuals with a known history of any of the following:\n\n8a. eosinophilic esophagitis\n\n8b. esophageal stricture unable to be passed with an upper endoscope\n\n8c. esophageal cancer\n\n8d. esophageal motility disorder (e.g., achalasia)\n\n8e. esophageal varices\n\n8f. esophageal or gastric surgery including fundoplication\n\n8g. neurologic cause of dysphagia (e.g., stroke, Parkinson s disease, etc.)\n\n8h. allergy to gelatin\n\n8i. inability to swallow pills\n\n9\\. Any condition that, in the investigator s opinion, places the individual at undue risk by participating in the study.\n\nCo-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator in consultation with the medical monitor. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.","ALL","18 Years","65 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background:\n\nEosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to the stomach. Diagnosing EoE currently requires a specialized tool called an endoscope. The esophageal string test (EST) is another test; the EST collects fluid from the upper digestive tract. An EST is simpler and cheaper than an endoscopy. Researchers want to know if an EST can diagnose EoE.\n\nObjective:\n\nTo test if the EST can diagnose EoE in people who have trouble swallowing.\n\nEligibility:\n\nAdults aged 18 to 65 years with trouble swallowing. They must have been born in the African continent or their parents were born in Africa.\n\nDesign:\n\nParticipants will be screened. They will give blood, stool, urine, and skin swab samples. They will complete surveys about their medical history, diet, symptoms, and home environment. They will bring a sample of their drinking water for testing.\n\nParticipants will have an EST. They will swallow a pill capsule that contains a nylon string. One end of the string will be taped to their cheek. The string will unravel down the esophagus and into the stomach. It will be pulled out after 1 hour. Fluids that soaked into the string will be tested.\n\nAt a different visit, participants will have an endoscopic exam. An endoscope is a flexible tube that is inserted down the mouth; it can be used to take tissue samples from the esophagus, stomach, and small intestine.\n\nParticipants will have a final visit in person, online, or by phone. They will take a survey and talk about their test results.",[28,29],"Dysphagia","Eosinophilic Esophagitis",[29,28,31],"Esophageal string test","RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":22},"2026-08-26",{"date":40,"type":22},"2027-08-31",{"name":42,"class":43},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",3,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100651988","ai-based-dysphagia-rehabilitation-program-development-and-validation-100651988","NCT07767123","AI-Based Dysphagia Rehabilitation Program: Development and Validation","Development and Validation of an Artificial Intelligence-Based Rehabilitation Program for Dysphagia","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Diagnosed with dysphagia, confirmed by clinical screening (e.g., abnormal Water Swallow Test) or instrumental assessment (e.g., FEES);\n3. Conscious and alert, without severe cognitive impairment, and capable of understanding instructions and cooperating with swallowing function assessments and rehabilitation therapy;\n4. Provision of informed consent, with the informed consent form signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Presence of impaired consciousness, coma, or severe cognitive impairment, rendering the patient unable to understand instructions or cooperate with assessments and treatments;\n3. Presence of severe psychiatric disorders, behavioral abnormalities, or severe aphasia\u002Fhearing impairment, preventing cooperation with swallowing function assessment and therapy;\n4. Presence of severe anatomical abnormalities of the upper respiratory or digestive tract (e.g., laryngeal\u002Fesophageal tumors, recent major head and neck surgery), which contraindicate FEES or conventional swallowing therapy;\n5. Medically unstable conditions (e.g., severe respiratory distress, hemodynamic instability, acute infection phase), rendering the patient unable to tolerate assessments or rehabilitation therapy;\n6. Temporary dysphagia caused by acute, reversible factors (e.g., acute alcohol or drug intoxication);\n7. Any other conditions deemed by the investigator as inappropriate for participation in this study.",true,{"count":54,"type":22},30,[25],"The goal of this clinical study is to learn if an artificial intelligence (AI)-assisted swallowing rehabilitation program can improve swallowing function in adults with dysphagia. It will also learn whether this approach can better detect aspiration (food or liquid entering the airway) and improve eating ability. The main questions it aims to answer are:\n\nCan AI-assisted analysis help identify swallowing treatment parameters that improve swallowing right away?\n\nDoes an optimized AI-assisted swallowing treatment work better than standard treatment parameters over 6 weeks?\n\nCan AI using data from sensors detect aspiration accurately?\n\nResearchers will compare swallowing function before and after treatment. They will also compare optimized treatment parameters selected with AI and FEES (a camera-based swallowing test) with standard treatment parameters. In addition, researchers will compare AI model results with FEES findings to see how well the sensors can identify aspiration.\n\nParticipants will:\n\nComplete swallowing assessments, including FEES, drinking tests, and swallowing questionnaires.\n\nHave small sensors placed to record muscle activity, sound, oxygen levels, and breathing while swallowing.\n\nReceive swallowing rehabilitation over 6 weeks, with treatment given in 1-week periods. During each period, treatment will be randomly assigned as either optimized parameters or standard parameters.\n\nComplete swallowing assessments after treatment periods to measure changes in swallowing function and eating ability.",[28],"NOT_YET_RECRUITING","2026-08-16",{"date":61,"type":36},"2026-08-19",{"date":63,"type":22},"2026-08",{"date":65,"type":22},"2027-12",{"name":67,"class":68},"National Research Center for Rehabilitation Technical Aids","OTHER",{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100652481","exploring-the-efficacy-of-the-effortful-swallow-maneuver-for-improving-swallowing-in-people-with-pd-100652481","NCT07773025","Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With PD","EFFORT-PD: Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With Parkinson Disease","EFFORT-PD","Inclusion Criteria:\n\n* Age 18 years or older\n* Neurologist-confirmed diagnosis of Parkinson disease\n* Self-report of one or more swallowing symptoms, such as difficulty managing secretions, coughing during meals, choking on food, or respiratory infection other than COVID-19 in the past 6 months\n* Baseline videofluoroscopic swallowing assessment showing prolonged time to laryngeal vestibule closure and\u002For poor pharyngeal area at maximum constriction on regular-effort swallows with thin or mildly thick liquid stimuli, relative to healthy reference values\n\nExclusion Criteria:\n\n* History of head and neck cancer\n* History of radical neck dissection, anterior cervical spine surgery, or neck\u002Foropharyngeal surgery, except tonsillectomy or adenoidectomy\n* History of any neurological disease other than Parkinson disease\n* Cognitive or receptive communication difficulties that preclude the ability to follow English-language study instructions\n* History of brain surgery, including deep brain stimulation",{"count":78,"type":22},74,[25],"The goal of this clinical trial is to learn whether a 4-week effortful swallow exercise program helps adults with Parkinson disease who have swallowing problems. The effortful swallow is a swallowing exercise where a person swallows with extra effort.\n\nResearchers will compare adults who start the exercise program right away with adults who start the program after a 4-week waiting period. All participants who remain eligible will have the opportunity to receive the exercise program.\n\nParticipants will have swallowing assessments, including video X-ray swallowing tests called videofluoroscopy. They will also complete questionnaires and take part in a remotely supervised swallowing exercise program with a speech-language pathologist. Participants who remain eligible and take part in the exercise program will use a tongue pressure device during practice. The main study period lasts about 10 weeks. Participants will also complete brief follow-up questionnaires at 6 months and 12 months.",[28,82],"Parkinson Disease (PD)",[28,84,85],"Parkinson disease","effortful swallow","2026-08-14",{"date":61,"type":36},{"date":89,"type":22},"2027-01-01",{"date":91,"type":22},"2030-08-31",{"name":93,"class":68},"University of Alberta",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100651262","comparison-of-sedated-and-unsedated-peg-in-elderly-asa-iv-patients-100651262","NCT07758153","Comparison of Sedated and Unsedated PEG in Elderly ASA IV Patients","Comparison Of Safety And Clinical Outcomes Of Sedated And Unsedated Percutaneous Endoscopic Gastrostomy Procedures İn ASA IV Elderly Patients: A Prospective Observational Cohort Study.","Inclusion Criteria:\n\n* Patients aged 65 years and older Patients classified as ASA physical status IV Patients with an indication for percutaneous endoscopic gastrostomy for long-term enteral nutrition Patients scheduled to undergo PEG placement in routine clinical practice Written informed consent obtained from the patient or legally authorized representative Availability of clinical, laboratory, procedural, and follow-up data\n\nExclusion Criteria:\n\n* Requirement for emergency PEG placement International normalized ratio greater than 1.5 Platelet count less than 50,000\u002Fmm³ Massive ascites Active peritonitis Previous total gastrectomy Pregnancy Refusal to participate in the study",{"count":21,"type":22},"OBSERVATIONAL","This prospective observational cohort study aims to compare the safety and clinical outcomes of sedated and unsedated percutaneous endoscopic gastrostomy procedures in elderly patients classified as ASA IV. The primary outcome is the development of cardiopulmonary complications within the first 24 hours after the procedure. Secondary outcomes include technical success, procedure duration, early procedure-related complications, length of hospital stay, intensive care requirement, 30-day mortality, and 30-day readmission.",[105,106,28,107,108],"Percutaneous Endoscopic Gastrostomy","Enteral Nutrition Feeding","Elderly Patients (>65 Years)","ASA Physical Status IV",[110,111,112,113,114],"Percutaneous endoscopic gastrostomy","Sedation","Unsedated PEG","ASA IV","Cardiopulmonary complications","2026-08-06",{"date":117,"type":36},"2026-08-11",{"date":119,"type":22},"2026-07-15",{"date":121,"type":22},"2027-07",{"name":123,"class":68},"Mersin University",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100649528","optimizing-dysphagia-treatment-delivery-in-acute-care-a-hybrid-efficacy-implementation-trial-100649528","NCT07736105","Optimizing Dysphagia Treatment Delivery in Acute Care: A Hybrid Efficacy Implementation Trial","Inclusion criteria for critically ill adults will be:\n\n1. Adult ≥ 18 years old\n2. Not pregnant\n3. Underwent a clinical flexible endoscopic evaluation of swallowing (FEES) or videofluoroscopy swallow study (VFSS) with a penetration aspiration scale (PAS) score ≥ 5\n4. Hospitalized in non-neuro intensive care unit (ICU) setting at Vanderbilt University Medical Center (VUMC) at some point during admission\n5. Dysphagia is primarily related to ICU stay and not other medical conditions that may cause dysphagia\n6. medically cleared with no contraindications for expiratory muscle strength training (EMST) or other treatments\n7. Cognitive capacity to follow basic directions\n8. Willing to undergo testing and treatment for the study.\n\nInclusion criteria for speech-language pathologists (SLPs) will be:\n\n1. Adult acute care speech-language pathologist who works at VUMC.\n2. Willing to complete surveys and\u002For participate in a focus group.",{"count":131,"type":22},120,[25],"This research study is investigating the efficacy and implementation of expiratory muscle strength training (EMST), standard of care dysphagia treatment, and intensive dysphagia treatment in critically ill adults in the acute care setting. Currently, no targeted, effective, and feasible dysphagia treatment approaches currently exist for use in critically ill adults in the acute care setting. The current study will investigate the impact of EMST, standard of care dysphagia treatment, and intensive dysphagia treatment on pulmonary function, cough function, swallow function, frailty, patient-reported swallow function, and health outcomes in critically ill adults. This study will also examine patient perceptions and clinical speech-language pathologists' perceptions of the acceptability, appropriateness, and feasibility of these interventions.\n\nCritically ill adults will: undergo tests of breathing, cough, and swallow function, complete questionnaires about the treatment, and their swallow function, and complete their respective treatment as prescribed.\n\nClinical speech-language pathologists will complete questionnaires about the interventions.\n\nA subset of critically ill adults and clinical speech-language pathologists will also have the opportunity to participate in focus groups.",[28,135],"Critical Illness",[28,137,138,139,140,141,142,135,143],"Swallowing","Deglutition","Deglutition Disorders","Swallowing Disorders","Breathing","Cough","Treatment","2026-07-29",{"date":146,"type":36},"2026-07-30",{"date":148,"type":22},"2027-04",{"date":150,"type":22},"2029-02",{"name":152,"class":68},"Vanderbilt University Medical Center",1,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":174,"leadSponsor":176,"locationsCount":153},"100629470","standardizing-swallow-pressure-measurements-100629470","NCT07475091","Standardizing Swallow Pressure Measurements","Pharyngeal High Resolution Manometry Standardization of Metrics","Inclusion Criteria:\n\n* without known swallowing disorders\n\nExclusion Criteria:\n\n* Known swallowing disorder\n* Allergy to topical anesthetic\n* Allergy to food relevant to study participation (e.g. lactose intolerance)\n* Inability to follow direction or remain calm during the experiment.","99 Years",{"count":7,"type":22},[25],"This study aims to directly compare and contrast swallowing pressure and impedance measurements obtained from two high-resolution manometry (HRM) systems: the Laborie LMT Pharyngeal System and the Medtronic ManoScan ESO HRM System in healthy adult volunteers. The primary objective is to determine how differences in catheter diameter, sensor configuration, and acquisition platforms influence measurement outcomes. Twenty-five healthy adults will participate in a single, approximately 2-hour visit; the study will be open for one year for data collection and two years for data analysis.",[28],[167,168,169,170],"pharyngeal pressure events","swallowing","measurement","diagnosis","2026-07-28",{"date":146,"type":36},{"date":63,"type":22},{"date":175,"type":22},"2027-06",{"name":177,"class":68},"University of Wisconsin, Madison",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100565189","phase-2-wearable-biofeedback-for-swallowing-disorders-rehabilitation-in-stroke-and-parkinson-disease-100565189","NCT06638944","Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease","Impact of Wearable Biofeedback for the Rehabilitation and Tele-rehabilitation of Neurogenic Dysphagia","Inclusion Criteria:\n\n* 50-90 years old\n* a confirmed (by a neurologist\u002Fphysician) diagnosis of stroke at least 3 months post event, or of PD (Hoehn and Yahr Stages II-IV)\n* score in the normal\u002Fmild range on the Montreal Cognitive Assessment (MoCA), determined during an in-house screening\n* confirmed oropharyngeal dysphagia, as evaluated during the intervention eligibility assessment by a certified and trained Speech Language Pathologist (SLP)\n* accuracy of exercise performance; as evaluated during the intervention eligibility assessment by a certified and trained SLP\n* independent (or with caregiver support) use of i-Phagia system post pre-intervention training session; as evaluated during the intervention eligibility assessment by a certified and trained SLP\n\nExclusion Criteria:\n\n* known allergy to barium or known\u002Fsuspected perforation or obstruction of the gastrointestinal (GI) tract\n* recent history of pneumonia (past 6 months)\n* head and neck surgery, radiation or trauma\n* a score in the moderate-severe range on MoCA (screened during in-house screening)\n* other neurological\u002Fneuromuscular disorders (e.g., multiple sclerosis, brain tumor, myositis, etc)\n* difficulty complying due to neuropsychological dysfunction determined during the in-house screening\n* currently enrolled in swallow or speech therapy\n* facial hair in the submental (under the chin) area and refusing to shave.\n* known allergies relating to the Ten20® Conductive Paste (this is the conductive paste used to help with sensors signal and adherence to the skin) and\u002For any of the sensor materials (gold\u002Facrylic) that come into contact with the skin\n* no oropharyngeal dysphagia; as evaluated during the intervention eligibility assessment by the certified and trained SLP\n* inability to perform the prescribed exercises accurately after a maximum of 12 practice trials; as evaluated during the intervention eligibility VFSS assessment by the certified and trained SLP\n* inability to use the system accurately post training (for i-Phagia groups); as evaluated during the intervention eligibility assessment by the certified and trained SLP\n* inability to safely swallow (without aspiration) at least one consistency; as evaluated during the intervention eligibility assessment by the certified and trained SLP","50 Years","90 Years",{"count":131,"type":22},[189],"PHASE2","Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible.\n\nTo start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head\u002Fneck and provide biofeedback to patients and adherence data to clinicians during swallow therapy. This system has been developed with commercially available and widely used materials and the Purdue University IRB has determined that the device is non-significant risk device.\n\nThe goal of this clinical trial is to learn if this biofeedback (using this new technology\u002Fi-Phagia) when used as an adjunct to a standard swallow therapy protocol works to improve swallowing function in patients post chronic stroke or diagnosed with Parkinson's disease. It will also help the investigators learn whether this therapy protocol is equally effective when provided in-person versus via telehealth. Finally, it will determine which patient factors may influence how well the treatment works.\n\nThe main questions it aims to answer are:\n\n* Does biofeedback (using this new technology\u002Fi-Phagia) when used as an adjunct to a standard swallow therapy protocol works better than a standard of care treatment to improve swallowing function in patients post chronic stroke or diagnosed with Parkinson's disease?\n* Is completing the swallow therapy protocol at home (via telehealth) as effective as completing it in-person (in the clinic)?\n* What factors related to the patients (e.g., age, diagnosis, etc.) may influence how well the treatment works?\n\nParticipants will:\n\n* Complete a 12-week swallow treatment protocol (12 treatment visits) either in-person or at home (via telehealth)\n* Complete 3 in-person evaluations (pre-treatment; post-treatment; and at a 12-week post treatment follow-up time point)\n* Exercise at home several days per week and keep a diary\u002Flog of their home exercise\n\nThe hypothesis is that upon study completion, the efficacy of sEMG biofeedback-facilitated swallow therapy for both in-person and telehealth service delivery in two neurogenic dysphagia populations will have been established, and variables determining response to treatment will begin to be identified.",[28,192,193],"Stroke","Parkinson Disease",[195,196,197,84,198,199,200],"biofeedback","dysphagia","oropharyngeal dysphagia","stroke","telehealth","wearable","2026-07-27",{"date":144,"type":36},{"date":204,"type":36},"2025-07-22",{"date":206,"type":22},"2029-04-30",{"name":208,"class":68},"University of Illinois at Urbana-Champaign",2,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":153},"100521498","comparative-study-between-fc-sems-and-pc-sems-in-the-palliation-of-dysphagia-due-to-malignant-neoplasm-of-esophagus-100521498","NCT06070376","Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.","Comparative Study Between Fully Covered Esophageal Prosthesis (FC-SEMS) and Partially Covered Esophageal Prosthesis (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.","Inclusion Criteria:\n\n* Patients with advanced malignant neoplasm of the esophagus, whether or not undergoing chemotherapy or radiotherapy;\n* Dysphagia score greater than 2 or presence of malignant esophagorespiratory fistula;\n* Indication of palliation of dysphagia through the placement of esophageal prostheses in a multidisciplinary meeting.\n\nExclusion Criteria:\n\n* Patients under 18 years;\n* Extraesophageal neoplasms;\n* Lesions with longitudinal extension less than 30 mm;\n* Previous treatment with esophageal prosthesis;\n* Tumors easily transposed to standard endoscope (9.8mm).",{"count":218,"type":22},34,[25],"Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer is dysphagia, associated or not with weight loss. Unfortunately, due to asymptomatic presentation in the early stages, more than half of patients are diagnosed in advanced stages of the disease, becoming ineligible for treatment with curative intent. In this sense, chemotherapy and radiotherapy are the pillars of palliative treatment, often regressing the injury and improving symptoms. However, some patients persist with dysphagia. In this scenario, esophageal prostheses are one of the main tools in the palliative treatment of esophageal cancer dysphagia, obtaining rapid and lasting relief of dysphagia. This study aims to compare fully covered (FC-SEMS) and partially covered (PC-SEMS) esophageal prostheses in this context, evaluating the number of reinterventions in each group, as well as the occurrence of adverse events. However, it is expected that with the data obtained it is possible to develop clearer and more effective protocols in the palliation of malignant dysphagia of esophageal stenosis.",[222,28],"Esophageal Neoplasms",[222,224,225],"Palliation of dysphagia","Esophageal stent","2026-07-16",{"date":228,"type":36},"2026-07-17",{"date":230,"type":36},"2023-06-26",{"date":232,"type":22},"2027-08-26",{"name":234,"class":68},"Instituto do Cancer do Estado de São Paulo",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":245,"conditions":246,"keywords":253,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100647742","nutritional-status-in-hospitalized-patients-over-65-years-of-age-with-mental-disorders-100647742","NCT07710456","Nutritional Status in Hospitalized Patients Over 65 Years of Age With Mental Disorders","Nutritional Status, Nutrition-Related Conditions, and Development of a Clinical Pathway for Nutritional Support in Hospitalized Patients Aged 65 Years and Older With Mental Disorders","NutriP-SI65","Inclusion Criteria:\n\n* Age 65 years and older\n* Presence of at least one psychiatric diagnosis\n* Hospitalization at the Geriatric Psychiatry Unit of the University Psychiatric Clinic Ljubljana\n\nExclusion Criteria:\n\n* Individuals who did not provide written informed consent (or whose legal representatives did not provide consent)\n* Hospitalization shorter than 48 hours\n* Presence of delirium\n* Patients receiving palliative care or who are terminally ill",{"count":244,"type":22},450,"The objective of of this observational study is to evaluate the nutritional status and the prevalence of nutrition-related conditions, as well as dysphagia, among patients aged 65 years and older with mental disorders. The study will also identify key associated factors and inform the development of targeted strategies for the prevention, early identification, and management of malnutrition and related conditions. Furthermore, a draft clinical pathway for nutritional care will be developed, and its feasibility and effectiveness will be assessed.",[247,248,249,250,251,28,252],"Malnutrition","Sarcopenia","Obesity","Sarcopenic Obesity","Frailty","Mental Disorder",[247,248,251,28,249,250,252,254],"Elderly","2026-07-13",{"date":228,"type":36},{"date":258,"type":22},"2026-06",{"date":65,"type":22},{"name":261,"class":68},"University Psychiatric Clinic Ljubljana",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":44},"100582677","phagenyx-registry-study-100582677","NCT06866418","Phagenyx® Registry Study","Phagenyx® Registry Study: Evaluating Swallowing Therapy Outcomes and Recovery in the U.S.","RESTORE-US","Inclusion Criteria:\n\n1. Phagenyx® System Group Patients: Patients underwent treatment with the Phagenyx® System for a minimum of 3 treatments.\n2. Control Group Patients: Patient requires a nasogastric feeding tube for severe dysphagia and required dysphagia treatment.\n3. Willing and able to provide appropriate informed consent (if required).\n\nExclusion Criteria:\n\n1. Primary endpoint outcome data not collected or not available.\n2. In the investigator or sponsor's opinion the patient is not considered suitable.\n3. Participation in another interventional study (medicinal or device) that could influence the outcomes of PES.\n4. Treatment of dysphagia with other forms of electrical stimulation.",{"count":271,"type":22},600,"A retrospective, open-label, matched-control registry study designed to characterize the effectiveness of Pharyngeal Electrical Stimulation (PES) to improve swallowing in patients with severe dysphagia post stroke when delivered using the Phagenyx® System in real-world clinical settings in hospitals in the United States of America (US).",[28],"2026-07-08",{"date":276,"type":36},"2026-07-09",{"date":278,"type":36},"2025-09-15",{"date":280,"type":22},"2036-09",{"name":282,"class":283},"Phagenesis Ltd.","INDUSTRY",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":153},"100627622","effect-of-an-oral-neuromuscular-training-device-on-dysphagia-100627622","NCT07451028","Effect of an Oral Neuromuscular Training Device on Dysphagia","Effect of an Oral Neuromuscular Training Device on Dysphagia: an Assessor-blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* First-ever stroke\n* Dysphagia assessed with the FOTT-SAS\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Tracheostomy tube\n* Admitted for short-term evaluation\n* Lack of ability to cooperate with mouth closure\n* Contraindications for using IQoro",{"count":292,"type":22},100,[25],"Dysphagia is a frequent complication following stroke, with an estimated prevalence of 42%. One training modality which have been implemented in both hospitals and municipalities for alleviating dysphagia are oral neuromuscular training devices. These devices are hand-held acrylic devices which are inserted between the lips and teeth by the patient or an assistant and pulled forward against lip pressure. According to the developers of one of these devices coined IQoro, the training strengthens the orofacial and pharyngeal muscles. One of recent studies by the developer of IQoro, have demonstrated a positive effect of IQoro in improving swallowing function and reducing clinical signs of aspiration among older people in intermediate care. However, aspiration risk was based on unblinded subjective water swallowing tests, and findings may therefore be biased. Additionally, it should be considered that the study was a cluster-randomized study, in which the intervention was performed in some care units, and the usual care was performed in other care units. Since usual care is not described in detail, results in favor of IQoro may also be due to differences in the usual care practice between care units. Focusing on individuals with stroke, only observational studies have been carried out. These studies have shown functional improvements in all four quadrants of the mouth, improved lip strength, and improved swallowing capacity. However, observational studies suffer from the inherent limitation that it is not possible to establish whether training with IQoro is actually the cause of these improvements.\n\nThe present research group recently published a small Randomized Controlled Trial (RCT), investigating the effectiveness of IQoro on swallowing function and decannulation in a very selective population of patients with cuffed tracheostomies due to severe acquired brain injury . Here, 22 subjects were randomized to either usual care, or usual care plus IQoro training as an add-on. In the study, there was no effect of IQoro in either time until decannulation, or swallowing function (as the implicit mechanism of action), compared with usual care. Patients with cuffed tracheostomy tubes are a very selective patient group, and results may not be generalized to a broader group of patients with post-stroke dysphagia.\n\nBased on this, more high-quality clinical trials with IQoro, on a broader population of patients with dysphagia admitted for neurorehabilitation is warranted, in order to clarify whether training with IQoro have an effect on swallowing.\n\nAim and hypothesis The aim of this study is to investigate the effectiveness of oral neuromuscular training with IQoro on swallowing function in patients with dysphagia due to stroke. The hypothesis is that patients will have improved swallowing function because of training with IQoro as an add-on to usual care, compared with patients who only receive usual care.\n\nStudy design An assessor-blinded randomized controlled trial. Study participants will be randomly assigned to either the IQoro (intervention group) or usual care (control group). The trial will be conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and approved by the Danish National Medical Research Ethics Committee",[28],[28,192,297],"Oral neuromuscular training","2026-07-06",{"date":300,"type":36},"2026-07-07",{"date":302,"type":36},"2026-06-01",{"date":304,"type":22},"2027-12-31",{"name":306,"class":68},"University of Aarhus",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":327,"locationsCount":44},"100647055","treatment-of-dysphagia-in-patients-with-dystrophic-epidermolysis-bullosa-with-budesonide-a-retrospective-bicentric-study-nice---paris-st-louis--necker-ebude-study-100647055","NCT07684105","Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis \u002F Necker (EBUDE Study)","EBUDE","Inclusion Criteria:\n\nPatients of both sexes, of any age, with EBD in dominant or recessive form, treated for at least one month with budesonide for dysphagia resistant to usual treatments.\n\nA description of the clinical form must be available in the file. The patient must assess the benefit of treatment at 1 and\u002For 3 months of Budesonide.\n\nPatients must be affiliated with social security. For adults, consent of non-opposition is required, and for minors, non-opposition from one of the parents or the person holding parental authority must be collected.\n\nExclusion Criteria:\n\nNo precise clinical or biological diagnosis. Treatment with Budesonide \\\u003C 1 month. No evaluation criteria in the file \u002F Objection to the use of data (withdrawal of non-opposition)","1 Year",{"count":316,"type":22},15,[25],"Budesonide is an anti-inflammatory medication that works by decreasing the immune system's overreaction. In the treatment of eosinophilic esophagitis, especially with Jorveza or a preparation made in a pharmacy, it reduces the production of substances responsible for inflammation in the esophagus. This action reduces the accumulation of certain inflammatory cells (eosinophils) and thus improves the symptoms and lesions of the esophagus.\n\nDystrophic epidermolysis bullosa (EBD) is a rare genetic disease that makes the skin and mucous membranes very fragile. Blisters, sores and wounds can appear as a result of even minor trauma. Scarring is often abnormal and can cause tissue to shrink or shrink.\n\nTo date, only two studies involving a total of eight children with EBD have evaluated a budesonide-based preparation. The results show an improvement in swallowing difficulties (dysphagia) as well as good tolerance of the treatment. However, there are currently no published data regarding the use of Jorveza in the form of an orally disintegrating tablet in adults with EBD.\n\nThrough the follow-up of patients treated at the MAGEC reference center, specialized in rare genetic diseases of the skin and mucous membranes, we aim to evaluate the interest and effects of budesonide treatment in individuals with EBD presenting with dysphagia.",[320,28,321],"Recessive Dystrophic Epidermolysis Bullosa","Esophageal Stenosis","2026-07-01",{"date":298,"type":36},{"date":322,"type":22},{"date":326,"type":22},"2027-06-30",{"name":328,"class":68},"Centre Hospitalier Universitaire de Nice",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":352,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":153},"100557838","marginal-ulcer-healing-with-low-thermal-argon-plasma-endoscopic-treatment-100557838","NCT06543316","Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","Accelerated Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","AMULET","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with a history of Roux-en-Y gastric bypass (RYGB) presenting symptoms indicative of marginal ulcers (MUs) such as abdominal pain, nausea, vomiting, gastrointestinal bleeding, or dysphagia.\n* Subjects must be scheduled for an EGD for the evaluation of these symptoms.\n* Marginal ulcers confirmed during the initial EGD.\n* Willingness to adhere to the SOC treatment, which includes PPIs.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent and understanding of study requirements.\n* Willingness and ability to attend required follow-up assessments at 4 weeks (+\u002F- 1 week) and 8 weeks (+\u002F- 2 weeks).\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Inability or unwillingness to comply with the SOC.\n* Current use of systemic antibiotics.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.",{"count":292,"type":22},[25],"The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.",[341,342,343,344,345,346,347,348,349,350,28,351],"Roux-en-y Anastomosis Site","Marginal Ulcer","Marginal Ulcer (Peptic) or Erosion","Ulcer","Ulcer, Gastric","Ulcer Gastrointestinal","Abdominal Pain","Nausea","Vomiting","GastroIntestinal Bleeding","Ulcer Gastrojejunal",[353,354,355,356,357,358,359],"Argon Plasma Coagulation","APC","Low-Thermal Argon Plasma Endoscopic Treatment","Endoscopy","RYGB","Roux-en-Y Gastric Bypass","Ulcer Healing","2026-06-23",{"date":362,"type":36},"2026-06-25",{"date":364,"type":36},"2025-03-04",{"date":366,"type":22},"2028-06",{"name":368,"class":68},"Christopher C. Thompson, MD, MSc",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":376,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":384,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":4},"100641065","efficacy-and-mechanism-of-yanjiu-needle-for-pharyngeal-dysphagia-based-on-semg-features-100641065","NCT07656025","Efficacy and Mechanism of 'Yanjiu Needle' for Pharyngeal Dysphagia Based on sEMG Features","Therapeutic Efficacy and Mechanistic Study of Yanjiu Acupuncture in Patients With Pharyngeal Dysphagia Based on Surface Electromyographic Features","Inclusion Criteria:\n\n* First onset of stroke with swallowing disorders lasting for 2 weeks to 6 months;\n* Stable vital signs, able to understand and execute physician instructions, and cooperate with treatment;\n* Age range: 40-75 years old, male or female not limited;\n* Functional Oral Intake Scale (FOIS) classification ≤ 4;\n* The patient's surgical site can receive acupuncture treatment;\n* Informed consent from patients or family members.\n\nExclusion Criteria:\n\n* Individuals with unstable vital signs who are unable to complete assessment and treatment;\n* Individuals with severe cognitive impairment, communication barriers, or other mental illnesses who are unable to cooperate with treatment;\n* Individuals with a history of oral, pharyngeal, and esophageal structural abnormalities, cricopharyngeal muscle stenosis, and cancer;\n* Confirmed by cranial CT\u002FMRI as a deceased with brainstem infarction\u002Fhemorrhage and extensive cerebral infarction;\n* Participants in other clinical trials;\n* Those who cannot accept surface electromyography examination; Pregnant and lactating women.","40 Years","75 Years",{"count":292,"type":22},[25],"Dysphagia is one of the most common and serious complications following stroke. It can easily lead to aspiration and aspiration pneumonia, reduce patients' quality of life, increase healthcare costs, and result in high mortality rates, making it a clinical issue that urgently needs to be addressed. Current mainstream therapies have limitations: neurostimulation targets a single pathway, while rehabilitation training offers only limited improvement in microcirculation and suffers from low patient compliance. Although acupuncture shows promise, it lacks high-quality randomized controlled evidence, and the specific acupuncture techniques lack standardized operational protocols, limiting their widespread adoption. In preliminary clinical practice, Chen Xiaokai, a renowned traditional Chinese medicine practitioner in Guangdong Province, developed the \"Nine Pharyngeal Acupoints\" (including Lianquan and Renying) based on the \"resolving knots\" theory. This approach can rapidly improve pharyngeal muscle tone and swallowing function. Basic research has confirmed that stimulation of these acupoints promotes pharyngeal circulation, activates the brainstem, and aids in the restoration of the swallowing reflex. This study aims to conduct a single-center, assessor-blinded, randomized, controlled, prospective superiority clinical trial. Using surface electromyography (EMG) as the core assessment tool, combined with swallowing videofluoroscopy and functional scales, the study will analyze the efficacy and neuro-muscular regulatory mechanisms of the \"Nine Pharyngeal Acupoints\" technique. The study is expected to clarify its therapeutic efficacy, establish standard operating procedures, and provide a basis for clinical implementation.",[382,28,383],"Acupuncture","Surface EMG",[192,28,385,382,386,387],"Nine needles for swallowing","Clinical research","mechanism","2026-06-16",{"date":390,"type":36},"2026-06-18",{"date":392,"type":22},"2026-06-20",{"date":394,"type":22},"2028-12-20",{"name":396,"class":68},"The Third People's Hospital of Huizhou",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":17,"minAge":404,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":153},"100641456","ai-enabled-mobile-app-for-safe-eating-in-older-adults-with-dysphagia-100641456","NCT07654088","AI-Enabled Mobile App for Safe Eating in Older Adults With Dysphagia","Efficacy of an AI-enabled Mobile Application for Safe Eating in Community-dwelling Older Adults With Dysphagia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 60 years or above\n* Community-dwelling (living in a home or community setting)\n* Suspected or clinically identified oropharyngeal dysphagia\n* Currently consuming food or liquids orally at texture-modified levels\n* Able to provide informed consent, or with caregiver support if mild cognitive impairment is present\n* Access to a smartphone or tablet, either independently or with caregiver assistance\n* Willing and able to participate in study procedures and follow-up assessments\n\nExclusion Criteria:\n\n* Exclusive dependence on non-oral feeding (e.g., tube feeding)\n* Severe cognitive impairment or severe visual impairment that prevents meaningful participation\n* Medical conditions or circumstances that make participation unsafe\n* Life expectancy less than 6 months\n* Current participation in another dysphagia-related interventional study\n* Use of other digital tools specifically designed for food texture classification during the study period","60 Years",{"count":406,"type":22},332,[25],"Difficulty swallowing (called dysphagia) is common in older adults and can make eating and drinking unsafe. It may lead to serious problems such as choking, lung infections, poor nutrition, and reduced quality of life. One common way to reduce these risks is to modify food and drink textures (for example, making foods softer or liquids thicker). However, people often find it difficult to prepare food at the correct texture level in everyday life, especially at home, which may reduce the effectiveness of this approach.\n\nThis study aims to test whether a smartphone application powered by artificial intelligence (AI) can help older adults with swallowing difficulties eat more safely. The app allows users (or their caregivers) to take a photo of food or drinks, and the app then estimates the texture level and provides guidance to help ensure it is safe to swallow. It also gives simple prompts to double-check food texture when needed.\n\nIn this clinical trial, community-dwelling adults aged 60 years or above with swallowing difficulties will be randomly assigned to one of two groups. One group will receive usual care, which includes education about safe swallowing and written instructions on appropriate food textures. The other group will receive the same usual care plus access to the AI-enabled mobile app for 16 weeks. Participants will continue their daily eating routines at home.\n\nThe main question this study is trying to answer is: Does using the AI-enabled mobile app improve how often people eat foods that match their recommended safe texture level compared with usual care alone?\n\nThe study will also examine whether the app helps reduce swallowing-related problems (such as choking), improves quality of life, and supports better overall eating ability. In addition, the study will evaluate how easy the app is to use and whether it places any burden on users.\n\nHypothesis: The researchers hypothesize that participants who use the AI-enabled app, in addition to usual care, will more consistently follow recommended food texture guidelines and experience safer eating compared with those who receive usual care alone.",[139,28],[28,411,412,413,414,415,416,417,418,419,420],"Deglutition disorders","Swallowing disorders","Texture modified diet","Food texture assessment","Artificial intelligence in health care","Clinical decision support systems","Digital health intervention","Older adults","Aging population","Mobile health applications","2026-06-12",{"date":423,"type":36},"2026-06-17",{"date":425,"type":22},"2028-01",{"date":427,"type":22},"2030-12",{"name":429,"class":68},"KAM Chi Shan Anna",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":153},"100560656","usefulness-and-feasibility-of-ultrasound-in-office-laryngology-procedures-100560656","NCT06579989","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures: A Pilot Study","Inclusion Criteria:\n\n* US-Guided Injection for Neurogenic Cough:\n\n  1. Age over 18 years\n  2. Recommended to undergo superior laryngeal nerve block\n* US-Assessment of Superior Laryngeal Nerve Anatomy\n\n  1. Age over 18 years\n  2. No cough complaints\n* US-Assessment of Injectate Volume:\n\n  1. Documentation of unilateral vocal fold paresis\u002Fparalysis or atrophy\n  2. Age over 18 years\n  3. Recommended to undergo injection laryngoplasty\n* US-Assessment of Swallow:\n\n  1. Age over 18 years\n  2. Presents with swallowing complaints\n* US-Assessment of Normal Swallow:\n\n  1. Age over 18 years\n  2. Presents without swallowing complaints\n* US-Assessment of Voice:\n\n  1. Age over 18 years\n  2. Undergoing evaluation of voice problems\n\nExclusion Criteria:\n\n1. Age under 18 years and over 99 years\n2. Open neck wound including tracheostomy",{"count":438,"type":22},200,[25],"Investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. Participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.",[142,442,443,444,28,445],"Vocal Cord Atrophy","Vocal Cord Paresis","Vocal Cord Paralysis","Dysphonia",{"date":388,"type":36},{"date":448,"type":22},"2027-01",{"date":450,"type":22},"2030-01",{"name":452,"class":68},"Weill Medical College of Cornell University",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":472,"leadSponsor":474,"locationsCount":153},"100638966","biomechanical-effects-of-emst-on-swallowing-function-in-parkinsons-disease-100638966","NCT07606547","Biomechanical Effects of EMST® on Swallowing Function in Parkinson's Disease","Biomechanical Effects of Expiratory Muscle Strength Training (EMST®) on Swallowing Function in Parkinson's Disease - a Prospective High-resolution Manometry Study","Inclusion Criteria:\n\n* diagnosis of Parkinson's disease,\n* PD-related dysphagia as objectively diagnosed with FEES\n\nExclusion Criteria:\n\n* severe dementia, not able to give consent\n* dysphagia related to other diagnoses",{"count":54,"type":22},[25],"The aim of this non-randomized intervention study is to investigate the detailed effects of a structured four-week EMST® training program on the biomechanics of swallowing function in dysphagic Parkinson's patients. A combination of fiberoptic endoscopic evaluation of swallowing (FEES) and pharyngeal high-resolution manometry (HRM) will be employed to comprehensively evaluate the neuromuscular changes in swallowing.",[464,28],"Parkinson's Disease (PD)",[28,466,467,468],"Expiratory muscle strength training","Parkinson's Disease","High-resolution pharyngeal manometry",{"date":470,"type":36},"2026-06-03",{"date":258,"type":22},{"date":473,"type":22},"2028-05",{"name":475,"class":68},"University Hospital Muenster",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":186,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":153},"100637459","effects-of-ctar-and-a-swallowing-pressure-ball-in-older-stroke-adults-100637459","NCT07620210","Effects of CTAR and a Swallowing Pressure Ball in Older Stroke Adults","Effectiveness of Combining Chin Tuck Against Resistance Swallowing Training and an Innovative Swallowing Pressure Measurement Ball on the Swallowing Function and Quality of Life in Home-Based Older Adults With Stroke","Inclusion Criteria:\n\n* Age between 65 and 90 years.\n* Diagnosed with ischemic or hemorrhagic stroke more than 6 months prior to enrollment.\n* Receiving home care services from participating home care agencies.\n* Able to follow instructions and participate in swallowing training.\n* MMSE score ≥24, or adjusted according to education level.\n* Passed the second stage of the 3-step swallowing screening test.\n* Presence of post-stroke dysphagia symptoms.\n\nExclusion Criteria:\n\n* History of head and neck cancer or head and neck radiotherapy.\n* History of cervical spine surgery or tracheostomy.\n* Severe neurological or neuromuscular diseases affecting swallowing function.\n* Severe unstable medical conditions.\n* Current use of medications significantly affecting swallowing function or muscle tone.\n* Unable to complete the intervention or follow-up assessments.\n* Receiving tube feeding without oral intake ability.",{"count":484,"type":22},132,[25],"This study aims to investigate the effectiveness of resistance swallowing rehabilitation using Chin Tuck Against Resistance (CTAR) exercises combined with an innovative swallowing pressure ball in improving swallowing function and swallowing-related quality of life among home-based older stroke patients with dysphagia.\n\nParticipants will receive a 12-week swallowing rehabilitation program conducted in the home-care setting. Outcome measures include swallowing function assessments, swallowing-related quality of life, and rehabilitation adherence. The study is designed as a randomized controlled trial to explore the feasibility and clinical benefits of resistance-based swallowing rehabilitation in community and home-care environments.",[192,28,488],"Post-Stroke Dysphagia",[490,491,492,493,494,495],"CTAR","Swallowing Rehabilitation","Swallowing Pressure Ball","Home Care","Older Adults","Stroke Rehabilitation",{"date":470,"type":36},{"date":498,"type":36},"2026-03-18",{"date":500,"type":22},"2027-02-28",{"name":502,"class":68},"Chimei Medical Center",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":153},"100530898","feasibility-of-early-swallowing-and-speech-intervention-for-head-and-neck-cancer-patients-treated-surgically-100530898","NCT06192771","Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically","ESSI-SURG","Inclusion Criteria:\n\n* Newly diagnosed patients with at least T2 stage tongue SCC who are planned for partial glossectomy and free flap reconstruction and are anticipated to achieve a post-operative independent oral intake.\n* Proficient in spoken and written English\n\nExclusion Criteria:\n\n* Patients who are planned for total glossectomy",{"count":511,"type":22},40,[25],"Oral cavity cancer (OCC) is one of the most common cancers worldwide, with tongue cancer being one of the most common subtypes. Patients with oral cancers can experience painful swallowing, swallowing difficulty (dysphagia), and associated weight loss long after surgery. Not only is dysphagia an independent predictor of quality of life (QoL) in cancer survivorship, it can also have a devastating impact on the health of patients resulting from complications such as pneumonia, malnutrition and feeding tube dependence. Emerging evidence suggests that patients undergoing surgery benefit from engaging with speech-language pathologists (SLPs) before problems arise, to learn swallow strategies that may become useful in their rehabilitation. This in turn has the potential to reduce complications and minimize the length of feeding tube dependency.\n\nThis study will assess the feasibility of conducting a prospective clinical trial that would evaluate the effects on patient health, function and overall benefit of early and systematic SLP speech and swallowing intervention for head and neck cancer patients planned for curative surgical treatment. We will also assess long-term changes in select clinical and patient-reported outcomes comparing their status before, and one month after, treatment.",[28,515],"Head and Neck Cancer",[196,517,518,519,520,521,522],"head and neck cancer","speech language pathology","surgery","speech","early intervention","medical outcomes",{"date":470,"type":36},{"date":525,"type":36},"2023-12-01",{"date":527,"type":22},"2026-12-31",{"name":529,"class":68},"University Health Network, Toronto",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":540,"conditions":541,"keywords":544,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":153},"100639039","ddk-acoustic-analysis-and-swallowing-indicators-100639039","NCT07626749","DDK Acoustic Analysis and Swallowing Indicators","Acoustic Analysis of Performance in Diadochokinetic (DDK) Tasks and Swallowing Function Indicators Among Adults Across Different Age Groups","AAP-DDK","Inclusion Criteria:\n\n* 1.Community-dwelling adults aged 18 years or older, with no upper age limit.\n* 2.Ability to communicate in Mandarin or Taiwanese and understand the study procedures.\n* 3.Willingness to provide written informed consent.\n* 4 .Ability to complete the DDK tasks and RSST.\n\nExclusion Criteria:\n\n* 1.Presence of acute respiratory infection, upper respiratory inflammation, or other acute conditions that may significantly affect speech or swallowing.\n* 2.Impaired consciousness, significant cognitive deficits, or inability to understand the study procedures.\n* 3.Recent surgery or radiotherapy involving the oral cavity or pharynx that affects speech or swallowing.\n* 4.Severe hearing impairment that prevents understanding of instructions.\n* 5.Any other condition deemed unsuitable for participation by the investigators.",{"count":539,"type":22},720,"This study examines whether simple speech tasks and a swallowing screening test can help identify swallowing risk in adults of different ages. Participants will complete basic questions, a swallowing self-assessment, a saliva swallowing test, and short voice recordings of rapid syllables. The study is non-invasive, takes about 75 minutes, and may help develop an easy, low-cost screening tool for early swallowing problems.",[542,543,28],"Swallowing Function","Swallowing Risk",[28,542,545,546,547,548,494],"diadochokinetic","Acoustic Analysis","Repetitive Saliva Swallowing Test","EAT-10","2026-05-29",{"date":551,"type":36},"2026-06-04",{"date":553,"type":22},"2026-06-15",{"date":555,"type":22},"2030-04-09",{"name":557,"class":68},"Kaohsiung Medical University",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":566,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":568,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":44},"100637338","maximizing-quality-of-life-after-cancer-through-rehabilitation-100637338","NCT07622407","Maximizing Quality of Life After Cancer Through Rehabilitation","A Transdisciplinary Interventions to MaximizE QuaLitY of Life After Cancer Through REHABilitation (TIMELY REHAB)","TIMELY REHAB","Inclusion Criteria:\n\nParticipants must be:\n\n* diagnosed with head and neck malignancy within the past 60 days;\n* prescribed a treatment plan at participating site that includes at least 1 dose of a cisplatin-based chemotherapy, or at least one dose of radiotherapy and\u002For surgery;\n* prescribed Intensive Dysphagia Therapy (IDT) at the participating site;\n* sufficient fluency in written English to be able to complete the study patient reported outcome questionnaires.\n\nExclusion Criteria:\n\nParticipants will be excluded is they have:\n\n* distant metastasis at enrollment;\n* diagnosis of second primary non-head and neck cancer in the thorax or the central nervous system at enrollment;\n* prior or planned total laryngectomy;\n* prior or planned cochlear implant;\n* head and neck radiotherapy for thyroid or cutaneous\u002Fskin primary tumors, regardless of neck fields;\n* cognitively or physically unable to participate (patient, physician or nurse report patient is incapable of participating), medical records indicate that participant exhibits aggressive behavior, participant has documented dementia, Alzheimer's disease, or severe psychosocial disorder, or notes indicate an individual is not legally capable of providing informed consent (participant has a legal guardian);\n* moderate\u002Fsevere dysphagia at enrollment per baseline videofluoroscopy DIGEST grade \\>=2;\n* severe\u002Fprofound hearing loss at enrollment per baseline audiogram;\n* exhibits Meniere's disease or retrocochlear disorder based on baseline hearing test results, patient report or notes in electronic medical records;\n* exhibits active or recent history of middle ear disorder based on otoscopy, tympanometry, baseline hearing test results, patient report, or medical record documentation;\n* unwilling to participate.","89 Years",{"count":78,"type":22},[25],"Treatment for head and neck cancer (HNC) often includes cisplatin chemotherapy and radiation. This treatment causes hearing loss and trouble swallowing in 70% of patients. If untreated, these symptoms increase stress and lower quality of life for survivors. Veterans with HNC usually get help for swallowing. However, damage to the hearing and balance systems-known as ototoxicity-is often missed or only addressed when it becomes very severe. To fill this gap, the investigators plan a clinical trial at two VA sites. The investigators compare the usual swallowing therapy alone to a new, more comprehensive program. This new program includes:\n\n1. the standard swallowing therapy,\n2. proactive management to protect hearing and balance or manage problems that can't be prevented, and\n3. other rehabilitation services based on a tele-oncology nurse's assessment. The hearing and balance intervention features quick screening tests and validated questionnaires to identify early signs of damage. These are given during cancer or radiation treatment visits to maximize convenience for the patient. Audiologists review these results remotely using tele-health technology. The investigators will also use new tools to predict and spot hearing problems that are personalized for each patient. The audiologist works closely with the patient and the care team to arrange further help if needed.\n\nThe tele-oncology nurse checks for other rehabilitation needs using a screening tool validated in Veterans, shares this information with the team, and advises patients about recommended care.\n\nThe investigators expect the results to show that managing hearing loss with swallowing therapy while improving care coordination for rehabilitation reduces survivors' stress and improves well-being compared to swallowing therapy alone.",[515,571,572,28],"Hearing Loss","Tinnitus",[574,575,576,577,515,578,28,579,580,572],"Audiology","Chemotherapy","Cisplatin","Drug-related side effects and adverse reactions","Ototoxicity","Professional practice gaps","Sensorineural hearing loss","2026-05-27",{"date":470,"type":36},{"date":584,"type":22},"2027-03-01",{"date":586,"type":22},"2030-06-30",{"name":588,"class":589},"VA Office of Research and Development","FED",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":607,"leadSponsor":609,"locationsCount":4},"100638430","transcutaneous-superior-laryngeal-nerve-stimulation-to-upregulate-swallowing-frequency-and-urge-to-swallow-in-patients-living-with-als-100638430","NCT07606235","Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in Patients Living With ALS","Inclusion Criteria:\n\n* Confirmed diagnosis of ALS (El-Escorial Criteria)\n* ALS FRS Bulbar Subscore of ≤ 10 and ≥ 3.\n* Functional Oral Intake scale score ≥ 2\n\nExclusion Criteria:\n\n* A diagnosis of significant cognitive impairment or frontotemporal dementia per the treating neurologist or neuropsychologist,\n* Current nasogastric tube placement\n* Current head and neck carcinoma\n* Pacemaker or implanted defibrillator or history of diagnosed arrhythmia, bradycardia, or repeated attacks of hypotension,\n* Implanted vagal nerve stimulator\n* Current pregnancy\n* History of epilepsy\n* Infected, broken or inflamed skin on the neck, or impaired sensation at the site of sEMG or TENS placement\n* Living greater than 50 miles from the NSU clinic round trip\n* Any clinical reason that this stimulation may not be a suitable treatment according to the principal investigator.",{"count":597,"type":22},5,[25],"Prospective, single-arm pilot study evaluating transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) in individuals with ALS.\n\nUp to 5 participants with confirmed ALS and bulbar involvement will be enrolled.\n\nPrimary outcomes: swallowing frequency and perceived urge to swallow. Participants complete a baseline visit, followed by two supervised treatment sessions within one week, and a final post-treatment evaluation.\n\nOptional visits (up to 2) may be used to individualize stimulation parameters prior to treatment.\n\nSwallowing function will be assessed using physiological monitoring, fiberoptic endoscopy, and videofluoroscopic swallow study (VFSS).\n\nTENS-SLN is a non-invasive neuromodulation approach targeting sensory pathways to facilitate swallowing without inducing muscle contraction.\n\nThis pilot study is designed to assess feasibility, safety, and preliminary effect sizes to inform future randomized trials, and is not powered to determine efficacy.",[601,28,602],"Amyotrophic Lateral Sclerosis (ALS)","Dystussia","2026-05-18",{"date":605,"type":36},"2026-05-26",{"date":258,"type":22},{"date":608,"type":22},"2026-12",{"name":610,"class":68},"Nova Southeastern University",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":52,"sex":17,"minAge":404,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":153},"100568198","swallowing-impairments-in-adults-with-and-without-alzheimers-disease-100568198","NCT06678100","Swallowing Impairments in Adults With and Without Alzheimer's Disease","Prevalence and Care Partner Burden of Individuals With Alzheimer's Disease","Inclusion criteria for AD cohort:\n\n1. adult ≥60 years old\n2. diagnosis of AD by a neurologist (confirmed with imaging, spinal tap, behavioral testing)\n3. no prior history of other neurological diseases (aside from stroke which has resolved with no current symptoms)\n4. no prior history of respiratory diseases\n5. no prior history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n6. consuming some form of oral intake\n7. able to follow basic directions\n8. able\u002Fwilling to provide consent\u002Fassent.\n\nExclusion Criteria for AD Cohort:\n\n1. individual \\\u003C60 years old\n2. Diagnosis of another type of dementia\n3. History of neurological\u002Frespiratory diseases\n4. History of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n5. not consuming any oral intake\n6. Unable to follow basic directions\n7. Unable to provide consent based on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC), score \\\u003C15 OR provide assent and a legal guardian\u002Fhealth care decision maker provides consent.\n\nInclusion criteria for care partners of individuals with AD will be:\n\n1. care partner of an individual with AD\n2. willing to complete questionnaires\u002Fparticipate in an interview.\n\nExclusion Criteria for Caregivers of Individuals with AD:\n\n1. not the primary caregiver of an individual with AD\n2. unwilling to complete questionnaires\u002Fsemi-structured interview\n\nInclusion criteria for community-dwelling adults will be:\n\n1. adult ≥60 years old\n2. no prior history of neurological diseases (aside from stroke which has resolved with no current symptoms)\n3. no prior history of respiratory diseases\n\n3\\) no prior history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region 4) no prior history of swallowing difficulties based on participant report. 5) Score ≥25th percentile based on sex\u002Fage\u002Feducation\u002Frace on the Montreal Cognitive Assessment (MOCA)\n\nExclusion Criteria for Healthy Cohort:\n\n1. individual \\\u003C60 years old\n2. history of neurological disease\n3. history of respiratory disease\n4. history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n5. history of swallowing difficulties\n6. Score \\\u003C25th percentile based on sex\u002Fage\u002Feducation\u002Frace on the Montreal Cognitive Assessment (MOCA)",{"count":619,"type":22},240,"This research study is investigating whether people with Alzheimer's disease (AD) experience more changes to swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe AD is high (85-93%), yet little is known about how swallow function evolves throughout the disease course in people with AD. The overall objective of this study is to evaluate swallowing function in adults with and without Alzheimer's disease. The investigator will also be involving the primary caregivers of individuals with Alzheimer's that are enrolled in the study to better understand the impact of swallowing impairments on the primary caregivers of those with Alzheimer's Disease.\n\nHealthy adults and individuals with Alzheimer's disease will:\n\n* undergo tests of cough and swallow function\n* undergo tests of grip and tongue strength\n* complete questionnaires\n\nCaregivers of individuals with Alzheimer's disease will also complete questionnaires.",[622,623,624,28],"Alzheimer Disease","Caregiver Burden","Healthy Aging","2026-05-06",{"date":627,"type":36},"2026-05-08",{"date":629,"type":36},"2025-04-21",{"date":631,"type":22},"2028-02",{"name":152,"class":68},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":23,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":153},"100567617","phase-2-corticosteroids-for-post-extubation-dysphagia-100567617","NCT06670521","Corticosteroids for Post-Extubation Dysphagia","Randomized Trial of Corticosteroids for Post-Extubation Aspiration","COPED","Inclusion Criteria:\n\n* Participant enrolled in primary study COMIRB #21-3873\u002F NCT # 05108896\n* Laryngeal edema identified on participants primary study Fiberoptic Endoscopic Evaluation of Swallowing (FEES) as defined as a revised Patterson edema score greater than zero\n* Admission to an ICU during their hospitalization\n* Mechanical ventilation with an endotracheal tube for greater than 48 hours.\n* Extubation except for compassionate extubation or transition to end-of-life care.\n\nExclusion Criteria:\n\n* Patient or provider refusal\n* Contraindication or corticosteroids defined as an allergic reaction (extremely rate) or taking other immunosuppressive medications.\n* Chronic treatment with corticosteroids (\\>= 40 mg Prednisone\u002Fday, \\>=32 Methylprednisolone\u002Fday)\n* Contraindication to enteral\u002Foral nutrition administration.\n* Pre-existing history of dysphagia or aspiration.\n* Pre-existing or acute primary central or peripheral neuromuscular disorder.\n* Presence of a chronic tracheostomy (present prior to ICU admission).\n* Pre-existing head and neck cancer or surgery.\n* Coagulopathy resulting in uncontrolled nasal or pharyngeal bleeding.\n* Delirium as assessed by CAM-ICU\n* Inability to obtain informed consent from patient or an appropriate surrogate.\n* Age \\\u003C18 years.",{"count":642,"type":22},80,[189],"This is a placebo-controlled, double-blind randomized trial of a short course of intravenous corticosteroids for Acute Respiratory Failure Survivors with Fiberoptic Endoscopic Evaluation of Swallowing (FEES) documented laryngeal edema. Study was leveraged using the existing R01 grant infrastructure COMIRB # 21-3873, study design, and research methods. Patients for the study proposed will have already been enrolled in the R01 longitudinal cohort study. The sites to perform this study include Colorado, BU, Yale, Tufts, and Stanford. Those R01-enrolled patients with laryngeal edema on their initial FEES examination: defined as the revised Patterson edema score greater than zero, will be approached for enrollment.",[28,646],"Laryngeal Edema","2026-05-04",{"date":625,"type":36},{"date":650,"type":36},"2024-12-02",{"date":652,"type":22},"2027-05-31",{"name":654,"class":68},"University of Colorado, Denver",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":23,"phases":665,"briefSummary":666,"conditions":667,"keywords":668,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":671,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":153},"100282760","dysphagia-evaluation-after-stroke--effect-oral-neuromuscular-training-on-swallowing-dysfunction-100282760","NCT02960737","Dysphagia Evaluation After Stroke- Effect Oral Neuromuscular Training on Swallowing Dysfunction","Dysphagia Evaluation After Stroke - a Randomized Controlled Trial of Oral Neuromuscular Training on Swallowing Dysfunction (DESIRE)","DESIRE","Inclusion Criteria:\n\n* Persistent dysphagia 12(±3) weeks after STROKE.\n\nExclusion Criteria:\n\n* Stroke patients with neurologic or psychiatric disorders or other diseases\u002Fconditions that can affect swallowing function.\n* Unable to collaborate due to other serious diseases and\u002For to affected general condition.",{"count":664,"type":22},60,[25],"The aim of this study is to investigate the effect of a specific rehabilitation program with an oral device used in stroke patients with persistent oral-and pharyngeal dysphagia.",[28,192],[28,192,669,297,670],"Intervention","Randomized control trial",{"date":627,"type":36},{"date":673,"type":36},"2022-12-01",{"date":675,"type":22},"2029-03",{"name":677,"class":68},"Umeå University"]